Document is current
Any future updates will be listed below
-
Authors
Abikhzer, Gad https://orcid.org/0000-0001-5280-6960
Treglia, Giorgio https://orcid.org/0000-0001-9808-780X
Pelletier-Galarneau, Matthieu https://orcid.org/0000-0001-6408-0511
Buscombe, John https://orcid.org/0000-0003-0121-5591
Chiti, Arturo https://orcid.org/0000-0002-5806-1856
Dibble, Elizabeth H. https://orcid.org/0000-0002-3906-6272
Glaudemans, Andor W. J. M. https://orcid.org/0000-0001-8081-0641
Palestro, Christopher J. https://orcid.org/0000-0002-5998-832X
Sathekge, Mike https://orcid.org/0000-0002-2806-0625
Signore, Alberto https://orcid.org/0000-0001-8923-648X
Jamar, Francois https://orcid.org/0000-0002-2106-958X
Israel, Ora https://orcid.org/0000-0001-6545-0924
Gheysens, Olivier https://orcid.org/0000-0001-8478-9675
- License Information
-
More Information
Article History
Received: 18 July 2024
Accepted: 2 September 2024
First Online: 10 October 2024
Declarations
:
: This guideline did not involve human participants or animals, and hence was exempt from institutional review board approval.
: Not applicable.
: Not applicable.
: Authors Mike Machaba Sathekge, Ora Israel, and Arturo Chiti are editors of this journal.GA: Novartis – Advanced Accelerator Applications- speaker honorariaGT: nothing to discloseMP-G: supported by a Fonds de recherche du Québec – Santé (FRQ-S) clinical research scholar awardJB: nothing to discloseAC: Novartis – Advanced Accelerator Applications, advisory boards and speaker honoraria; Sirtex, speaker honorarium; General Electric Healthcare, speaker honorarium; Telix, advisory board; Bracco, speaker honorarium; European Journal of Nuclear Medicine and Molecular Imaging, Editor in ChiefEHD: nothing to discloseAWJMG: nothing to discloseCJP: nothing to discloseMS: nothing to discloseAS: nothing to discloseFJ: nothing to discloseOI: GE Healthcare- consultantOG: nothing to disclose
